Significantly, recent clinical trials with IL-17 antagonists in established RA show up to 42% ACR50 responses with short duration therapy [14], providing the first direct evidence in humans of a pathological role of IL-17 in RA, and indicating that blockade of IL-17 in humans may be a valid therapeutic approach. The gene discussed is IL17A; the disease is rheumatoid arthritis.